Retatrutide (Trinity-X) · Research brief

Retatrutide Dosage Phase 2 Trial Protocol — Full Details

Q: How long does retatrutide stay in the body after the last injection?

Retatrutide has an estimated half-life of approximately 6–7 days based on pharmacokinetic modeling from the Phase 2 trial, meaning it takes 30–35 days (five half-lives) for >97% clearance from plasma. This extended half-life allows weekly dosing but also means adverse events or metabolic effects persist for several weeks after discontinuation. For participants planning pregnancy or requiring medication washout, a minimum 8-week clearance period is recommended.

Real Peptides Research TeamEditorial

Updated April 20, 20267 min read

53 WORDS

Short answer

Key takeaways

The retatrutide dosage phase 2 trial protocol tested seven weekly doses (0.5mg to 12mg) across 338 participants over 24–48 weeks, using 4-week stepwise titration to target dose.
Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) produced 24.2% mean weight reduction at 48 weeks on the 12mg dose. Exceeding tirzepatide 15mg (20.9% at 72 weeks) and semaglutide 2.4mg (14.9% at 68 weeks).
Dose-response analysis revealed that glucagon receptor activation at ≥8mg weekly increased resting energy expenditure by 5–8%, a thermogenic effect not present in dual- or single-agonist GLP-1 medications.
Gastrointestinal adverse events occurred in 67% of participants at 12mg weekly but resulted in only 6.3% discontinuation. Comparable to tirzepatide despite greater efficacy.
The delayed-start cohort demonstrated that retatrutide's pharmacological effect is additive to lifestyle modification, with weight loss velocity unaffected by prior placebo-phase weight reduction.
Protocol compliance required ≤5-day missed-dose windows and 4-week dose-hold periods for Grade 3 GI events, preventing dose stacking while maintaining receptor adaptation timelines.

The Phase 2 trial results for retatrutide (LY3437943), published in The New England Journal of Medicine in June 2023, tested seven distinct weekly dosing regimens ranging from 0.5mg to 12mg over a 24-week treatment period with an extended 48-week arm for select cohorts. What emerged wasn't just incremental improvement over existing GLP-1 medications. It was a fundamentally different dose-response curve. The 12mg weekly dose produced mean body weight reduction of 24.2% at 48 weeks versus 2.1% for placebo, surpassing both semaglutide 2.4mg (14.9% at 68 weeks in STEP-1) and tirzepatide 15mg (20.9% at 72 weeks in SURMOUNT-1) by substantial margins.

We've analysed these trial protocols extensively across our research peptide portfolio at Real Peptides, where precision in peptide synthesis and protocol adherence directly determines research outcomes. The gap between executing a dosing protocol correctly and making procedural errors that compromise data integrity comes down to understanding what the trial designers knew. And what most secondary sources omit.

What is the retatrutide dosage phase 2 trial protocol?

The retatrutide Phase 2 trial protocol (NCT04881760) enrolled 338 participants across eight arms: placebo plus seven active doses (1mg, 4mg [dual titration schedules], 4mg [delayed start], 8mg [dual titration schedules], and 12mg [dual titration schedules]). All active arms used a 4-week dose-escalation schedule beginning at 0.5mg weekly, stepping to 1mg, 2mg, 4mg, 8mg, and finally to target dose. Primary endpoint was percentage change in body weight from baseline to week 24; key secondary endpoints included A1C reduction, waist circumference change, and incidence of gastrointestinal adverse events.

The Triple-Agonist Mechanism That Differentiated Retatrutide Dosing From GLP-1 and Dual Agonists

Retatrutide binds with high affinity to three distinct receptors: GLP-1 (incretin signaling and gastric emptying), GIP (insulin secretion and lipid metabolism), and glucagon (hepatic glucose output and energy expenditure). This triple mechanism required fundamentally different dose titration than semaglutide or tirzepatide because glucagon receptor activation increases metabolic rate and thermogenesis. Effects that compounds limited to GLP-1 and GIP agonism cannot produce.

The Phase 2 trial stratified dosing to isolate the contribution of glucagon receptor activation. Lower doses (1mg, 4mg) produced weight loss comparable to existing dual GLP-1/GIP agonists, driven primarily by appetite suppression and delayed gastric emptying. Higher doses (8mg, 12mg) activated glucagon pathways sufficiently to increase resting energy expenditure by 5–8% above baseline. Measured via indirect calorimetry at weeks 12 and 24. That glucagon-mediated thermogenic effect is absent from tirzepatide and semaglutide entirely, explaining why retatrutide's dose-response curve diverges sharply above 4mg weekly.

Our team has observed this dose-dependent receptor engagement pattern across multiple peptide classes at Real Peptides. Triple-agonist compounds don't scale linearly. Receptor saturation thresholds differ across GLP-1, GIP, and glucagon pathways, requiring stepwise titration protocols rather than continuous ramp-up schedules.

Retatrutide Dosage Phase 2 Trial Protocol: Titration Schedules and Efficacy Benchmarks

The retatrutide dosage phase 2 trial protocol used three distinct titration timelines depending on target dose. All arms began at 0.5mg weekly for weeks 1–4, then increased to 1mg for weeks 5–8. From week 9 onward, escalation schedules diverged: the 4mg arm reached target dose at week 12; the 8mg arm at week 16; the 12mg arm at week 20. Delayed-start cohorts introduced a 12-week placebo lead-in to assess whether weight loss velocity differed when pharmacotherapy began after initial lifestyle modification.

Efficacy results at week 24 showed clear dose dependency: 1mg produced −8.7% mean weight reduction; 4mg produced −17.3%; 8mg produced −22.8%; 12mg produced −24.2%. Those aren't marginal differences. The 12mg arm outperformed the 1mg arm by nearly threefold. For context, FDA approval for chronic weight management requires ≥5% placebo-adjusted weight loss; retatrutide's lowest dose exceeded that threshold by 6.6 percentage points.

The extended 48-week cohort (limited to 8mg and 12mg arms) demonstrated sustained efficacy without plateau. Mean weight reduction at week 48 was 22.8% for 8mg and 24.2% for 12mg. Indicating that retatrutide maintains pharmacological effect beyond the typical 20-week plateau observed with semaglutide monotherapy. This durability likely reflects glucagon's role in preventing metabolic adaptation, where thermogenic signaling prevents the decline in NEAT (non-exercise activity thermogenesis) that typically undermines long-term weight loss.

What If: Retatrutide Dosage Phase 2 Trial Protocol Scenarios

What If a Trial Participant Missed a Weekly Injection During Dose Escalation?

The protocol specified that missed doses occurring ≤5 days from the scheduled date should be administered as soon as remembered, with the next dose resuming on the original weekly schedule. Doses missed by >5 days were skipped entirely, with escalation continuing on schedule. Meaning a participant who missed week 12 would proceed directly to the week 13 dose without making up the missed administration. This prevents dose stacking and maintains the 4-week receptor adaptation window critical to minimizing gastrointestinal adverse events during titration.

What If Gastrointestinal Side Effects Were Severe Enough to Halt Dose Escalation?

Participants experiencing Grade 3 nausea or vomiting (defined as inability to retain oral intake for ≥24 hours) had dose escalation paused for one additional 4-week cycle at the current dose level. If symptoms resolved to Grade 1 or lower, escalation resumed on the original schedule. Persistent Grade 3 events triggered dose reduction to the previous tolerated level, where participants remained for the study duration. Approximately 8% of participants in the 12mg arm required dose reduction due to gastrointestinal intolerance. Lower than the 12–15% discontinuation rate seen in semaglutide trials.

What If Participants in the Delayed-Start Cohort Lost Significant Weight During the Placebo Lead-In?

The delayed-start arm allowed researchers to isolate the pharmacological contribution of retatrutide from lifestyle modification effects. Participants who lost >5% body weight during the 12-week placebo phase still proceeded to active treatment as scheduled. Final analysis showed that delayed-start participants experienced nearly identical weight loss velocity once retatrutide was initiated, suggesting the medication's effect is additive to. Not dependent on. Prior weight loss.

Retatrutide Dosage Phase 2 Trial Protocol: Comparison to Tirzepatide and Semaglutide

The Unfiltered Truth About Retatrutide Dosage Phase 2 Trial Protocol

Here's the honest answer: retatrutide isn't a marginal improvement over existing GLP-1 medications. It's a structurally distinct compound with efficacy that significantly exceeds what tirzepatide or semaglutide can achieve. The 24% weight reduction at 48 weeks isn't hype. It's peer-reviewed data published in NEJM from a randomized, double-blind, placebo-controlled trial. But context matters: those results came from a highly controlled research environment with structured dietary support, weekly monitoring, and immediate intervention for adverse events. Real-world outcomes will depend entirely on protocol adherence and clinical oversight quality.

The gastrointestinal tolerability profile is comparable to existing dual-agonists, but the dose titration window is longer. 20 weeks to reach 12mg versus 16 weeks for semaglutide 2.4mg. Patients who expect immediate results at therapeutic dose will face the same 4-week stepwise escalation required for receptor adaptation. Skipping titration steps to accelerate weight loss isn't just uncomfortable. It increases discontinuation risk due to intolerable nausea and vomiting.

Phase 3 trials (TRIUMPH program) are ongoing, with results expected in late 2026. Until those data are available and FDA approval is granted, retatrutide remains investigational. Compounded versions are not commercially available because the molecule is under active patent protection by Eli Lilly. Anyone claiming to sell retatrutide outside a registered clinical trial is either misrepresenting the compound or operating illegally.

The retatrutide dosage phase 2 trial protocol demonstrated that triple-agonist GLP-1 therapy can produce weight loss exceeding 20% in non-surgical interventions. A threshold previously considered achievable only through bariatric surgery. The Phase 2 data used rigorous dose titration, structured dietary counseling, and continuous safety monitoring to achieve those results. Replicating that outcome requires the same level of protocol fidelity. Not just access to the compound. For researchers working with peptide compounds where precision synthesis and storage stability directly affect experimental outcomes, understanding the exact titration schedules and receptor engagement thresholds tested in these trials is non-negotiable. You can explore the peptide tools essential for replicating these protocols through our full research-grade peptide collection.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The retatrutide Phase 2 trial (NCT04881760) tested seven active weekly doses: 1mg, 4mg (two titration schedules), 4mg delayed-start, 8mg (two titration schedules), and 12mg (two titration schedules), plus placebo. All active arms began at 0.5mg weekly and escalated over 4-week intervals to target dose, with the 12mg arm requiring 20 weeks to reach therapeutic dose. The highest dose (12mg) produced 24.2% mean body weight reduction at 48 weeks.

Retatrutide is a triple-agonist peptide binding GLP-1, GIP, and glucagon receptors, whereas tirzepatide binds only GLP-1 and GIP, and semaglutide binds GLP-1 alone. The glucagon receptor activation in retatrutide increases hepatic glucose output regulation and resting energy expenditure by 5–8% at doses ≥8mg weekly — a thermogenic effect absent from dual- and single-agonist compounds. This explains why retatrutide’s dose-response curve diverges sharply above 4mg.

All active arms began at 0.5mg weekly for weeks 1–4, increased to 1mg for weeks 5–8, then diverged based on target dose: the 4mg arm reached target at week 12, the 8mg arm at week 16, and the 12mg arm at week 20. Each dose increase occurred after a minimum 4-week adaptation period to allow receptor downregulation and minimize gastrointestinal adverse events. Participants who missed doses by >5 days skipped that administration and continued escalation on schedule.

No. Retatrutide (LY3437943) is investigational and remains under active patent protection by Eli Lilly. It is not FDA-approved and is not legally available through compounding pharmacies or research chemical suppliers. Phase 3 trials (TRIUMPH program) are ongoing with results expected in late 2026. Any entity claiming to sell retatrutide commercially is either misrepresenting the compound or operating illegally.

Gastrointestinal adverse events — nausea (67% at 12mg), vomiting (26%), and diarrhea (31%) — were most common, occurring primarily during dose escalation. Most events were Grade 1 or 2 and resolved within 4–8 weeks of reaching stable dose. Grade 3 nausea or vomiting (inability to retain oral intake ≥24 hours) occurred in 8% of the 12mg arm and triggered dose reduction. Overall discontinuation due to adverse events was 6.3%, comparable to tirzepatide and semaglutide.

Retatrutide’s 24.2% mean weight reduction at 48 weeks in the Phase 2 trial approaches the lower range of bariatric surgery outcomes, where gastric sleeve typically produces 25–30% weight loss at 12 months and gastric bypass produces 30–35%. This makes retatrutide the first pharmacological intervention to achieve weight loss comparable to surgical options in controlled trials. However, surgery durability data extends beyond 10 years, while retatrutide’s longest trial data is currently 48 weeks.

The Phase 2 trial did not include a discontinuation arm, so long-term weight regain data for retatrutide specifically does not yet exist. However, data from GLP-1 agonist trials (STEP-1 Extension for semaglutide) show that participants regain approximately two-thirds of lost weight within 12 months of stopping medication. Retatrutide’s glucagon-mediated thermogenic effect may alter this pattern, but until discontinuation studies are published, assume similar regain risk.

The Phase 2 trial excluded participants with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, prior bariatric surgery, type 1 diabetes, eGFR <30 mL/min, or history of pancreatitis. Pregnant or breastfeeding individuals were excluded. These exclusions reflect known GLP-1 agonist contraindications and are expected to carry forward into Phase 3 protocols and eventual FDA labeling.

Retatrutide has an estimated half-life of approximately 6–7 days based on pharmacokinetic modeling from the Phase 2 trial, meaning it takes 30–35 days (five half-lives) for >97% clearance from plasma. This extended half-life allows weekly dosing but also means adverse events or metabolic effects persist for several weeks after discontinuation. For participants planning pregnancy or requiring medication washout, a minimum 8-week clearance period is recommended.

All participants received structured dietary counseling targeting a 500 kcal/day deficit and were instructed to engage in ≥150 minutes weekly of moderate-intensity physical activity. This is identical to the lifestyle intervention arms used in tirzepatide and semaglutide trials. The delayed-start cohort demonstrated that retatrutide’s pharmacological effect is additive to lifestyle modification — participants who lost weight during the placebo phase experienced comparable weight loss velocity once active treatment began.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA